What is the Rubicon Research PE ratio today?
Rubicon Research's PE ratio is 89.5 at the 29 October 2026 close (₹1,559.30 a share): a market capitalisation of ₹25,788 crore divided by consolidated net profit of ₹288 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹247 crore) it is 104.5.
What is the Rubicon Research net worth?
Rubicon Research's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,289 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹25,788 crore at the 29 October 2026 close.
What is the Rubicon Research book value per share?
Rubicon Research's book value per share was ₹77.93 on 31 March 2026: shareholders' equity of ₹1,289 crore divided by the 16.54 crore shares in issue. The share price at the 29 October 2026 close was ₹1,559.30.
What is the Rubicon Research PB ratio (price to book value)?
Rubicon Research's price-to-book (PB) ratio is 20.01 at the 29 October 2026 close: a market capitalisation of ₹25,788 crore divided by shareholders' equity (book value) of ₹1,289 crore on 31 March 2026. That is a book value of ₹77.93 per share against a share price of ₹1,559.30.
Is Rubicon Research debt free?
No. Rubicon Research had borrowings of ₹259 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.20. Its cash and current investments were ₹346 crore, so it held net cash of ₹86.6 crore.
What is the Rubicon Research shareholding pattern?
On 30 September 2026, Rubicon Research's shares were held by promoters 51.25%, foreign portfolio investors (FII/FPI) 9.01%, domestic institutions (DII) 15.72% (including mutual funds at 13.78%) and retail and other non-institutional investors 24.02%.
What is the Rubicon Research market cap?
Rubicon Research's market capitalisation was ₹25,788 crore at the 29 October 2026 close: 16.54 crore shares at ₹1,559.30 each.
What is the Rubicon Research debt to equity ratio?
Rubicon Research's debt-to-equity ratio was 0.20 on 31 March 2026: borrowings of ₹259 crore against total equity of ₹1,289 crore.
What is the Rubicon Research dividend in 2026 and its record date?
In 2026, Rubicon Research has declared one dividend: ₹1.50 with record date 7 August 2026.
What is the Rubicon Research EPS?
Rubicon Research's basic earnings per share (EPS) were ₹15.52 in FY26.
What is the Rubicon Research promoter holding?
Promoters held 51.25% of Rubicon Research on 30 September 2026, down 8.51 percentage points from 59.76% the previous quarter, according to the shareholding pattern filed with NSE.
What is the Rubicon Research free cash flow?
In FY26, Rubicon Research generated ₹205 crore of cash from operations and spent ₹229 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹24.1 crore.
What are the Rubicon Research latest quarterly results?
Rubicon Research's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹84.8 crore; revenue from operations ₹534 crore.
What is the Rubicon Research revenue and profit in FY26?
In FY26 (April 2025–March 2026), Rubicon Research's consolidated net profit was ₹247 crore, on revenue from operations of ₹1,754 crore.
When are the Rubicon Research next results?
Rubicon Research will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
How does Rubicon Research compare with its peers?
On FY26 consolidated figures, against Shilpa Medicare, Sun Pharma Advanced Research and Strides Pharma Science: Rubicon Research's operating margin of 20.2% is the third highest of the four (Shilpa Medicare 20.5%, Sun Pharma Advanced Research 84.5%, Strides Pharma Science 14.9%; peer average 40.0%).
How does the Rubicon Research PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Rubicon Research's PE ratio is 104.5, the highest of the four: Shilpa Medicare 75.2, Sun Pharma Advanced Research 3.8 and Strides Pharma Science 18.2, a peer average of 32.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Rubicon Research vs Shilpa Medicare: how do they compare?
In FY26, Rubicon Research earned net profit of ₹247 crore on revenue of ₹1,754 crore, against ₹243 crore on ₹1,539 crore for Shilpa Medicare. Rubicon Research's operating margin was 20.2% (Shilpa Medicare 20.5%). At the 29 October 2026 close, Rubicon Research's market capitalisation was ₹25,788 crore against ₹18,291 crore for Shilpa Medicare, and its PE ratio on FY26 profit 104.5 against 75.2.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
